Heal Faster

Basic Info

Why Rescuderm?

Rescuderm is a groundbreaking innovation developed by scientists that is transforming the way we understand and treat skin trauma and burns.

Its effectiveness comes from targeting the TRPV1 receptor: a receptor found throughout the skin, the body’s largest organ, where it plays a critical role in the body’s response to injury and trauma.

The TRPV1 receptor is widely recognized for its involvement in pain perception, heat and acidity detection, inflammation, and the wound-healing process. [i] [ii] [iii] [iv]

It also plays a key role in the local release of neuropeptides, which contribute to the inflammation commonly experienced in burns and other skin injuries. [v] For many years, scientists have explored ways to regulate pain sensation and provide relief through the TRPV1 receptor - Rescuderm found a way. [vi]

How does Rescuderm work?

Protons are among the few molecules capable of binding to the TRPV1 receptor. In fact, the body naturally releases protons at certain times to activate these receptors, serving as part of the body’s own response to pain and injury. [vii] [viii][ix]

Rescuderm is built on this scientific understanding. Its formulation is designed to interact with the TRPV1 receptor, competing with the body’s natural pain-signaling processes that occur following skin trauma or burns. [x]

This effect is achieved through Rescuderm’s unique “proton flux” technology, engineered to deliver a controlled flow of protons to the affected area and the local TRPV1 receptors. [xi]

What should I expect when I use Rescuderm?

When applied to a fresh wound, Rescuderm immediately targets and binds to activated TRPV1 receptors associated with pain and inflammation, helping interrupt the body’s natural pain-signaling response.

Users typically experience an initial tingling sensation upon application. This is a result of TRPV1 receptor activation. With continued interaction, these receptors become desensitized, helping stabilize and reduce pain over time.

As discomfort subsides, visible symptoms such as redness, swelling, and burning sensations may also diminish. These effects have been documented through clinical trials and collaborative studies conducted with researchers from University of Toronto, University of Guelph, and Defence Research and Development Canada.

The Rescuderm formula was also engineered to dry into a protective layer over time if you don't intend to re-apply. This creates a barrier that not only helps reduce germ proliferation, but also shields the affected area from external contaminants — functioning like a second skin.

Essentially, Rescuderm is designed as an all-in-one skin treatment focused on TRPV1-related injury, trauma, and burn care.

Simple, non-toxic, fragrance-free

In addition to supporting the body’s natural healing response and helping protect against infection, Rescuderm is non-prescription, Health Canada approved (NHP-DIN #80026886), food-grade, non-toxic, and formulated using simple, carefully selected ingredients.

We believe in complete transparency when it comes to our product and the science behind it. Feel free to explore our site for more information or contact us directly with any questions via the "Contact Us" page.

[i] Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997 Oct 23;389(6653):816-24. doi: 10.1038/39807. PMID: 9349813.

[ii] Gouin O, L'Herondelle K, Lebonvallet N, Le Gall-Ianotto C, Sakka M, Buhé V, Plée-Gautier E, Carré JL, Lefeuvre L, Misery L, Le Garrec R. TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation: pro-inflammatory response induced by their activation and their sensitization. Protein Cell. 2017 Sep;8(9):644-661. doi: 10.1007/s13238-017-0395-5. Epub 2017 Mar 31. PMID: 28364279; PMCID: PMC5563280.

[iii] Bagood MD, Isseroff RR. TRPV1: Role in Skin and Skin Diseases and Potential Target for Improving Wound Healing. Int J Mol Sci. 2021 Jun 7;22(11):6135. doi: 10.3390/ijms22116135. PMID: 34200205; PMCID: PMC8201146.

[iv] Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron. 1998 Sep;21(3):531-43. doi: 10.1016/s0896-6273(00)80564-4. PMID: 9768840.

[v] Jhaveri MD, Elmes SJ, Kendall DA, Chapman V. Inhibition of peripheral vanilloid TRPV1 receptors reduces noxious heat-evoked responses of dorsal horn neurons in naïve, carrageenan-inflamed and neuropathic rats. Eur J Neurosci. 2005 Jul;22(2):361-70. doi: 10.1111/j.1460-9568.2005.04227.x. PMID: 16045489.

[vi] Khairatkar-Joshi N, Szallasi A. TRPV1 antagonists: the challenges for therapeutic targeting. Trends Mol Med. 2009 Jan;15(1):14-22. doi: 10.1016/j.molmed.2008.11.004. Epub 2008 Dec 25. PMID: 19097938.

[vii] Lee BH, Zheng J. Proton block of proton-activated TRPV1 current. J Gen Physiol. 2015 Aug;146(2):147-59. doi: 10.1085/jgp.201511386. Epub 2015 Jul 13. PMID: 26170176; PMCID: PMC4516785.

[viii] Lee BH, Zheng J. Proton block of proton-activated TRPV1 current. J Gen Physiol. 2015 Aug;146(2):147-59. doi: 10.1085/jgp.201511386. Epub 2015 Jul 13. PMID: 26170176; PMCID: PMC4516785.

[ix] Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. 2001 Sep 13;413(6852):203-10. doi: 10.1038/35093019. PMID: 11557989.

[x] Martineau L, Dosch HM. Management of bioburden with a burn gel that targets nociceptors. J Wound Care. 2007 Apr;16(4):157-64. doi: 10.12968/jowc.2007.16.4.27028. PMID: 17444381.

[xi] Hazan A, Kumar R, Matzner H, Priel A. The pain receptor TRPV1 displays agonist-dependent activation stoichiometry. Sci Rep. 2015 Jul 21;5:12278. doi: 10.1038/srep12278. PMID: 26194846; PMCID: PMC4508619.